David Montani (10/14/1976), MD, PhD is Professor at the French National Referral Centre for Pulmonary Hypertension in the Department of Respiratory Medicine headed by Pr Marc Humbert, at the Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris-Saclay University, France.

His main research interest is in the field of pulmonary vascular diseases in particularly in the management of pulmonary veno-occlusive disease (PVOD), pulmonary arterial hypertension (PAH) associated with drug exposure, PAH associated with orphan pulmonary diseases and genetics (BMPR2, ACVRL1, NF1, TBX4, SOX17, FLNA) of PAH and PVOD. D. Montani has developed a screening program of pulmonary hypertension in asymptomatic subjects carrying a genetic susceptibility to PAH/PVOD in the French PAH network. He leads the center of Rare pulmonary diseases (OrphaLung network) in Bicetre Hospital. He has been the senior Chair of the Taskforce on "Definition, classification and diagnosis of PH" of the 7th World Symposium on PH (Barcelona 2024).

In addition, Pr. Montani leads a basic research team in the INSERM UMR-S999 laboratory «Pulmonary Hypertension: Pathophysiology and Novel Therapies» (Centre Chirurgical Marie Lannelongue, Le Plessis Robinson), led by Prof. Marc Humbert, his work focusing on the pathophysiology of heritable and drug-induced PAH and PVOD.

David Montani is currently the Vice President of the French-speaking Respiratory Society (Société de Pneumologie de Langue Française, SPLF).

He has published >500 (h-Factor 79) articles mainly on pulmonary hypertension (genetics, drugs-associated PAH, pulmonary rare diseases, basic science) and is Editor-in-Chief of Respiratory Medicine and Research (https://www.editorialmanager.com/resmer) and member of the editorial board of ERJ Open Research (https://openres.ersjournals.com/journal/editorial-board).